The GLP-1 weight loss market is one of the fastest-growing segments in healthcare. Demand for medications like semaglutide and tirzepatide has outpaced supply for years, and a large portion of the potential patient population still has no access to treatment. For entrepreneurs and clinic owners, this creates a rare window to build a durable, recurring-revenue healthcare business at a time when patient demand is structurally high.
This guide covers everything you need to understand before launching: the market opportunity, how compounded GLP-1 medications work and their legal status, how the business model functions, what you need to get started, the economics of a GLP-1 program, and the regulatory guardrails you must operate within.
The GLP-1 Market Opportunity
The scale of the weight loss market is difficult to overstate.
Obesity affects more than 40% of American adults, according to data from the Centers for Disease Control and Prevention. For decades, durable pharmacological treatment options were limited. GLP-1 receptor agonists changed that. Clinical trials for semaglutide showed average weight loss of approximately 15% of body weight over 68 weeks, with some patients losing significantly more. Tirzepatide, a dual GLP-1/GIP receptor agonist, has shown average weight loss exceeding 20% in Phase III trials published in the New England Journal of Medicine.
Market projections reflect this clinical momentum. Research firms have projected the global GLP-1 market will exceed $100 billion annually by the early 2030s, with weight management representing the largest growth driver. Demand is being sustained by a combination of direct-to-consumer awareness, social media, and word-of-mouth from patients seeing real results.
The addressable patient population in the United States alone is in the tens of millions. Most have not yet received treatment due to cost, insurance barriers, or lack of access to a prescribing provider. This gap is the opportunity.
Understanding Compounded GLP-1 Medications
What Compounding Means
Compounded medications are prepared by licensed pharmacies using active pharmaceutical ingredients (APIs) according to a prescription. They are not FDA-approved finished drug products, but compounding is a legal and established practice in American medicine governed by the Federal Food, Drug, and Cosmetic Act.
For GLP-1 programs, the most relevant medications are compounded semaglutide and compounded tirzepatide. These are prepared using the same active pharmaceutical ingredients found in brand-name products, but manufactured by compounding pharmacies rather than Novo Nordisk or Eli Lilly.
Why Compounded GLP-1 Became a Market
Brand-name semaglutide (Ozempic, Wegovy) costs between $900 and $1,500 per month at retail without insurance. Insurance coverage is inconsistent and often requires extensive prior authorization. This price point puts the treatment out of reach for most cash-pay patients.
During the period when semaglutide was listed on the FDA Drug Shortage Database, compounding pharmacies were legally permitted to produce compounded versions. Compounded semaglutide programs typically price in the $150 to $350 per month range, dramatically expanding the accessible patient population.
Tirzepatide remains on the FDA drug shortage list as of this writing, which continues to support compounding pathways for that molecule.
Compounded vs Brand-Name: Key Differences
| Factor | Compounded | Brand-Name |
|---|---|---|
| FDA approval status | Not approved | Approved |
| Monthly cost (cash-pay) | $150-$350 | $900-$1,500 |
| Insurance coverage | None | Possible |
| Dose flexibility | High | Fixed doses |
| Formulation options | Custom | Standard |
| Manufacturing oversight | 503A or 503B | FDA-regulated cGMP |
For most cash-pay weight loss programs, compounded GLP-1 is the commercial foundation. It makes the program affordable at a price point that works for patients and generates margin for the business.
The Business Model: How GLP-1 Clinics Make Money
A GLP-1 weight loss clinic is fundamentally a subscription healthcare business. Revenue comes primarily from monthly program fees paid by patients who remain on treatment.
The basic model works as follows:
- Acquire the patient through paid advertising, organic search, referral, or existing practice relationships
- Complete intake including a medical questionnaire, eligibility screening, and lab review if required
- A licensed prescriber conducts a consultation and issues a prescription for an appropriate GLP-1 medication
- A compounding pharmacy fulfills the prescription and ships directly to the patient
- The patient pays a monthly program fee that covers the medication, provider access, and ongoing monitoring
- The patient continues monthly as long as they are achieving results and want to continue
The business earns margin on the spread between what it costs to deliver the program (medication, prescriber time, platform, support) and what the patient pays per month. Retention is the central driver of profitability because patient acquisition costs are typically paid back over the first two to three months of subscription.
Additional Revenue Streams
Beyond the core GLP-1 subscription, many successful programs generate additional revenue from:
- Lab work and diagnostic panels
- Adjunct medications (B12 injections, appetite suppressants)
- Metabolic coaching or registered dietitian consultations
- Transition programs when patients reach their goal weight
- Other hormone optimization programs (TRT, thyroid optimization)
The multi-program approach increases revenue per patient and improves retention by addressing multiple health goals within one relationship.
What You Need to Launch
Launching a GLP-1 weight loss business requires four core components. None of them require you to be a clinician yourself.
1. A Clinical Platform
You need software to manage patient intake, eligibility screening, provider workflows, prescriptions, and ongoing communication. Building this from scratch is expensive and time-consuming. White-label platforms designed for GLP-1 programs come pre-built with the intake forms, clinical decision support, and pharmacy integrations that would otherwise take months to develop.
2. A Prescribing Network
Every prescription must be written by a licensed provider. If you are not a clinician, you have two options: hire or contract a prescriber, or use a platform that includes access to a prescriber network. A contracted prescriber network covering all 50 states allows you to serve patients nationally without being limited to a single prescriber’s state licensure.
3. A Compounding Pharmacy Partner
Your pharmacy partner ships medication directly to patients. Choosing the right pharmacy matters: evaluate them on quality testing documentation, turnaround time, patient communication, and compliance posture. Work only with pharmacies that conduct third-party potency and sterility testing and can provide certificates of analysis on request. Review the FDA’s guidance on compounding pharmacy oversight before selecting a partner.
4. A Patient Acquisition Strategy
Paid digital advertising, specifically Meta and Google, is the primary patient acquisition channel for most GLP-1 programs. SEO and content marketing build longer-term acquisition at lower cost per patient. Referral programs and partnerships with existing medical practices are highly capital-efficient once established. Budget for customer acquisition costs of $100 to $300 per patient in a competitive digital market.
Economics: Revenue Model and Patient LTV
Understanding the unit economics before you launch is essential.
Sample Program Economics
Assume a program price of $249 per month, which is competitive for a compounded semaglutide program that includes the medication, provider access, and support.
With a monthly churn rate of 8% (which is reasonable for a well-run program with good clinical outcomes), average patient lifetime is approximately 12 months. At $249 per month, average patient lifetime value is approximately $3,000.
If you are acquiring patients at $150 per patient, your payback period is less than two months and your return on acquisition spend is roughly 20x over the patient lifetime.
Scale Economics
| Monthly Active Patients | Monthly Revenue | Annual Revenue |
|---|---|---|
| 100 | ~$24,900 | ~$299,000 |
| 250 | ~$62,250 | ~$747,000 |
| 500 | ~$124,500 | ~$1,494,000 |
| 1,000 | ~$249,000 | ~$2,988,000 |
These projections assume 100% of patients on a $249/month plan with 8% monthly churn. Real programs will have a mix of plan prices, varying churn rates, and growth in both directions. The point is that scale multiples quickly because the marginal cost of adding a patient is low once the platform, prescribing, and pharmacy infrastructure is in place.
Key Metrics to Track
- Monthly Recurring Revenue (MRR): Total active subscriptions per month
- Patient Acquisition Cost (PAC): Total marketing spend divided by new patients acquired
- Monthly Churn Rate: Percentage of active patients who cancel each month
- Patient Lifetime Value (LTV): Average revenue per patient over their retention period
- LTV:PAC Ratio: Target 3:1 or higher for a sustainable business
Regulatory Landscape: What You Must Know
FDA Compounding Rules
The FDA governs compounding pharmacies through Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act. 503B outsourcing facilities can only compound copies of brand-name drugs during an active shortage. 503A pharmacies compound patient-specific prescriptions and may have separate legal pathways.
The FDA declared the semaglutide shortage resolved in February 2025. Ongoing court challenges from compounding industry groups have created uncertainty about enforcement timelines. Tirzepatide remains in shortage. Monitor the FDA Drug Shortages page regularly and ensure your pharmacy partners provide updated compliance documentation.
State Prescribing and Telehealth Rules
Telehealth prescribing rules vary by state. Most states allow GLP-1 prescriptions via synchronous or asynchronous telehealth, but some require specific consent procedures or limit certain prescribing categories via telehealth. Your prescribing network or legal counsel should maintain state-by-state compliance documentation.
HIPAA and Data Privacy
Any platform handling patient health information must comply with HIPAA. This includes your intake forms, communication tools, prescribing workflows, and any third-party analytics or advertising pixels on patient-facing pages. Conduct a HIPAA risk assessment before launch and ensure Business Associate Agreements are in place with all technology and pharmacy partners.
Truth in Advertising
The FTC and FDA both regulate health claims in advertising. Avoid unsubstantiated outcome claims (“lose 30 pounds in 30 days”) and ensure all claims about medications are supported by clinical evidence. Review the FTC’s health products compliance guidance before running paid media campaigns.
Building for Retention, Not Just Acquisition
Many operators focus disproportionately on acquiring new patients and underinvest in retention. This is a mistake. At 8% monthly churn, your program replaces its entire patient base in about 13 months. Reducing churn from 8% to 5% increases average patient lifetime by nearly 8 months and increases LTV by roughly 60%.
Retention drivers in GLP-1 programs include:
- Proactive check-ins when patients approach the typical dropout window (weeks 4 to 8)
- Dosing flexibility to manage side effects
- Clear expectation setting about the weight loss timeline
- Regular outcome tracking that shows patients their own progress
- A clear answer to “what happens when I reach my goal weight”
Programs that invest in clinical support and patient communication consistently outperform acquisition-focused programs on LTV and profitability.
How Karpa Health Helps You Launch
Karpa Health provides the complete infrastructure for launching and scaling a GLP-1 weight loss business. The platform includes white-label patient intake, a 50-state licensed prescriber network, integrated pharmacy fulfillment, and the practice management tools needed to run a compliant, scalable program.
You bring the brand and the patients. Karpa Health provides the clinical and operational backbone.
Learn more about the GLP-1 weight loss solution or explore the entrepreneur program designed specifically for non-clinical founders entering the GLP-1 market.
If you are ready to talk through your specific situation, visit karpahealth.com/for/entrepreneur to get started.
For more context on closely related topics, read semaglutide telehealth brand launch guide, tirzepatide telehealth brand launch guide, and cash-pay revenue model guide for GLP-1 and peptides.
Start your brand if you are ready to launch with Karpa Health.